Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 20,000 shares of the stock in a transaction on Tuesday, November 7th. The shares were sold at an average price of $210.59, for a total transaction of $4,211,800.00. Following the completion of the sale, the director now owns 536,717 shares of the company’s stock, valued at approximately $113,027,233.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Illumina, Inc. (ILMN) opened at $209.61 on Friday. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $214.50. The company has a market cap of $30,835.20, a PE ratio of 61.75, a price-to-earnings-growth ratio of 3.49 and a beta of 0.74.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.99 by $0.12. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The company had revenue of $714.00 million for the quarter, compared to the consensus estimate of $692.77 million. During the same period last year, the company posted $0.97 EPS. The firm’s quarterly revenue was up 17.6% compared to the same quarter last year. equities research analysts predict that Illumina, Inc. will post 3.75 earnings per share for the current year.

WARNING: This piece of content was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/10/jay-t-flatley-sells-20000-shares-of-illumina-inc-ilmn-stock.html.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Zeke Capital Advisors LLC boosted its stake in shares of Illumina by 60.2% in the 3rd quarter. Zeke Capital Advisors LLC now owns 2,574 shares of the life sciences company’s stock valued at $513,000 after purchasing an additional 967 shares in the last quarter. Amalgamated Bank boosted its stake in shares of Illumina by 2.3% in the 3rd quarter. Amalgamated Bank now owns 17,564 shares of the life sciences company’s stock valued at $3,499,000 after purchasing an additional 388 shares in the last quarter. Twin Capital Management Inc. acquired a new stake in shares of Illumina in the 3rd quarter valued at approximately $812,000. Cadence Capital Management LLC acquired a new stake in shares of Illumina in the 3rd quarter valued at approximately $799,000. Finally, Axiom International Investors LLC DE boosted its stake in shares of Illumina by 60.9% in the 3rd quarter. Axiom International Investors LLC DE now owns 186,457 shares of the life sciences company’s stock valued at $37,142,000 after purchasing an additional 70,572 shares in the last quarter. Institutional investors own 93.07% of the company’s stock.

Several brokerages have recently weighed in on ILMN. Wells Fargo & Company reissued a “market perform” rating and issued a $205.00 price objective (up from $200.00) on shares of Illumina in a research report on Wednesday, October 25th. First Analysis raised shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 price objective on the stock in a research report on Wednesday, August 2nd. Zacks Investment Research lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Barclays PLC reissued an “equal weight” rating and issued a $150.00 price objective on shares of Illumina in a research report on Wednesday, August 9th. Finally, Canaccord Genuity reissued a “hold” rating and issued a $170.00 price objective on shares of Illumina in a research report on Wednesday, July 26th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $200.88.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.